Silence Therapeutics (SLN)

Silence Therapeutics (SLN) Financial Statements


Silence Therapeutics Financial Overview

Silence Therapeutics's market cap is currently ―. The company's EPS TTM is $-1.433; its P/E ratio is -9.45; Silence Therapeutics is scheduled to report earnings on March 13, 2024, and the estimated EPS forecast is $-0.08. See an overview of income statement, balance sheet, and cash flow financials.
Dec 22Sep 22Jun 22Mar 22Dec 21
Income Statement-
Total Revenue£ 4.76M£ 3.37M£ 3.64M£ 5.72M£ 3.41M
Gross Profit£ 906.00K£ 977.00K£ 1.29M£ 3.45M£ 1.37M
EBIT£ -15.04M£ -9.29M£ -13.42M£ -9.57M£ -11.30M
EBITDA£ -14.90M£ -9.18M£ -13.31M£ -9.46M£ -11.24M
Net Income Common Stockholders£ -13.76M£ -7.10M£ -11.94M£ -7.68M£ -9.43M
Balance Sheet-
Cash, Cash Equivalents and Short-Term Investments£ 71.14M£ 90.02M£ 51.56M£ 59.30M£ 73.54M
Total Assets£ 107.50M£ 124.04M£ 83.40M£ 86.78M£ 96.19M
Total Debt£ 446.00K£ 499.00K£ 52.00K£ 90.00K£ 137.00K
Net Debt£ -70.70M£ -89.52M£ -51.51M£ -59.20M£ -73.40M
Total Liabilities£ 85.43M£ 89.91M£ 88.14M£ 82.79M£ 87.67M
Stockholders Equity£ 22.07M£ 34.13M£ -4.74M£ 3.99M£ 8.53M
Cash Flow-
Free Cash Flow£ -13.71M£ -9.45M£ -8.30M£ -14.43M£ -2.75M
Operating Cash Flow£ -13.41M£ -9.40M£ -8.27M£ -14.38M£ -2.21M
Investing Cash Flow£ -16.41M£ -42.00K£ -35.00K£ -51.00K£ 4.45M
Financing Cash Flow£ 44.00K£ 43.06M£ -11.00K£ -47.00K£ 0.00
Currency in GBP

Silence Therapeutics Earnings and Revenue History

Silence Therapeutics Debt to Assets

Silence Therapeutics Cash Flow

Silence Therapeutics Forecast EPS vs Actual EPS

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis